ID: ALA1945267

Max Phase: Preclinical

Molecular Formula: C15H15ClN6O

Molecular Weight: 330.78

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1ncc(Cn2cc(COc3ccc(Cl)cc3)nn2)c(N)n1

Standard InChI:  InChI=1S/C15H15ClN6O/c1-10-18-6-11(15(17)19-10)7-22-8-13(20-21-22)9-23-14-4-2-12(16)3-5-14/h2-6,8H,7,9H2,1H3,(H2,17,18,19)

Standard InChI Key:  VXNDVDGSHXDPKZ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 330.78

Molecular Weight (Monoisotopic): 330.0996

AlogP: 2.24

#Rotatable Bonds: 5

Polar Surface Area: 91.74

Molecular Species: NEUTRAL

HBA: 7

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 5.97

CX LogP: 2.22

CX LogD: 2.20

Aromatic Rings: 3

Heavy Atoms: 23

QED Weighted: 0.77

Np Likeness Score: -1.80

References

1. He J, Feng L, Li J, Tao R, Wang F, Liao X, Sun Q, Long Q, Ren Y, Wan J, He H..  (2012)  Design, synthesis and biological evaluation of novel 2-methylpyrimidine-4-ylamine derivatives as inhibitors of Escherichia coli pyruvate dehydrogenase complex E1.,  20  (5): [PMID:22305934] [10.1016/j.bmc.2012.01.019]

2. He H, Wang W, Zhou Y, Xia Q, Ren Y, Feng J, Peng H, He H, Feng L..  (2016)  Rational design, synthesis and biological evaluation of 1,3,4-oxadiazole pyrimidine derivatives as novel pyruvate dehydrogenase complex E1 inhibitors.,  24  (8): [PMID:26972920] [10.1016/j.bmc.2016.03.011]

3. Feng J, He H, Zhou Y, Guo X, Liu H, Cai M, Wang F, Feng L, He H..  (2019)  Design, synthesis and biological evaluation of novel inhibitors against cyanobacterial pyruvate dehydrogenase multienzyme complex E1.,  27  (12): [PMID:30692021] [10.1016/j.bmc.2019.01.021]

Source

Source(1):

• Scientific Literature